EKR Therapeutics, Inc., an emerging specialty pharmaceutical company, has completed its first institutional financing led by NewSpring Capital and ESP Equity Partners. EKR will be led by Howard Weisman, former founder, President and Director of ESP
Pharma, formed in 2002 and sold to PDL BioPharma for over $500 million. Mr. Weisman,
Chairman and CEO of the company, is joined by EKR co-founders Cathy Kerzner and
Richard DeSimone, who will serve as President and Chief Financial Officer, respectively.
Genetic
Engineering News
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Biom’up’s Laparoscopic Applicator Earns New Marketing Approval
The device quickly delivers Hemoblast powder to bleeding areas in minimally-invasive surgeries.
Lawmakers Want Probe of BMS/Celgene Deal
The cancer drugs the company will acquire as part of the deal include Celgene’s blockbuster drug Revlimid.
FDAnews Drug Daily Bulletin
ESP PHARMA FOUNDER LAUNCHES EKR THERAPEUTICS WITH FINANCING LED BY NEWSPRING CAPITAL AND ESP EQUITY PARTNERS
June 28, 2006
